Celcuity's Upcoming Conferences: Investors Take Note!

Celcuity Inc. Announces Key Participation in Investor Conferences

Celcuity Inc. (NASDAQ: CELC), a pioneering biotechnology company, focuses on developing targeted therapies for oncology. Recently, the Chief Executive Officer and Co-founder, Brian Sullivan, has announced exciting opportunities for investors to engage with the company at upcoming conferences. Investors will have a chance to attend one-on-one meetings and participate in fireside chats where insights into the company's strategic direction and innovations will be revealed.

Scheduled Conferences

Brian Sullivan will present at the TD Cowen 45th Annual Health Care Conference. This event is set to take place in Boston and will commence at 10:30 a.m. ET on a date in early March. Investors unable to attend in person need not worry, as a live webcast will be available for streaming online.

Following that, Mr. Sullivan will also participate in a fireside chat at the Leerink Global Healthcare Conference, also happening in Miami at 9:20 a.m. ET shortly thereafter. This series of engagements is an excellent opportunity for investors to get a closer look at Celcuity's innovative initiatives in cancer treatment.

About Celcuity's Innovations

At the heart of Celcuity's approach is its lead therapeutic candidate, gedatolisib. This medication is a potent dual inhibitor that targets the PI3K and mTOR pathways, critically important in cancer biology. What sets gedatolisib apart is its unique mechanism of action and pharmacokinetic properties. It stands to make a significant impact in the treatment of various solid tumors.

Currently, a Phase 3 clinical trial, named VIKTORIA-1, is evaluating gedatolisib in combination with fulvestrant, and possibly palbociclib, for patients suffering from HR+/HER2- advanced breast cancer. This trial is actively enrolling participants, marking a significant step forward in the fight against this challenging condition. A wealth of additional information regarding the study is available on ClinicalTrials.gov.

Looking Ahead at Future Trials

Celcuity is also planning to initiate a Phase 3 trial, VIKTORIA-2, which aims to explore gedatolisib combined with a CDK4/6 inhibitor and fulvestrant as a first-line treatment for HR+/HER2- advanced breast cancer. This trial is expected to begin patient enrollment in the second quarter of 2025, which shows Celcuity’s commitment to advancing cancer treatment protocols.

Corporate Headquarters and Additional Information

Celcuity operates out of Minneapolis, where it champions cutting-edge biotechnology research to develop innovative cancer therapies. Interested parties can find further details about the company and its initiatives by visiting their official website.

Contact Information

For more inquiries, stakeholders can reach out to:

Brian Sullivan, CEO
Celcuity Inc.
Email: bsullivan@celcuity.com
Phone: (763) 392-0123

Vicky Hahne
Email: vhahne@celcuity.com

For media inquiries, contact ICR Healthcare:
Patti Bank
Email: patti.bank@icrhealthcare.com
Phone: (415) 513-1284

Frequently Asked Questions

1. What is Celcuity Inc. focused on?

Celcuity Inc. focuses on developing targeted therapies specifically for cancer treatment, emphasizing innovative approaches to treat solid tumors.

2. Who will represent Celcuity at the investor conferences?

Brian Sullivan, the Chief Executive Officer and Co-founder, will represent Celcuity at the upcoming investor conferences.

3. What is the significance of gedatolisib?

Gedatolisib is Celcuity's lead therapeutic candidate and works as a dual inhibitor for cancer treatment, offering a unique mechanism of action compared to existing therapies.

4. How can investors participate in the conferences?

Investors can attend Brian Sullivan's presentations and one-on-one meetings at the events or view the live webcasts that will be made available online.

5. Where is Celcuity headquartered?

Celcuity Inc. is headquartered in Minneapolis, where it conducts its biotechnology research and development activities.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.